

Michael Hutchinson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6546813/michael-hutchinson-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

17,992
citations

46
h-index

133
g-index

217
ext. papers

20,338
ext. citations

5.8
avg, IF

6.01
L-index

#	Paper	IF	Citations
210	Perceived and objective cognitive impairment in newly diagnosed versus established multiple sclerosis: impact of disease duration. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1149-1154	1.9	1
209	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. <i>Frontiers in Neurology</i> , 2021 , 12, 646841	4.1	2
208	Response to "isolated head tremor: A DAT SPECT and somatosensory temporal discrimination study." <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 166-167	3.6	2
207	Stress and Dystonia. <i>Movement Disorders</i> , 2021 , 36, 1794	7	
206	Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study. <i>Journal of Sleep Research</i> , 2021 , 30, e13159	5.8	1
205	Non-motor features of cervical dystonia: Cognition, social cognition, psychological distress and quality of life. <i>Clinical Parkinsonism & Related Disorders</i> , 2021 , 4, 100084	0.9	3
204	We Must Talk about Sex and Focal Dystonia. <i>Movement Disorders</i> , 2021 , 36, 604-608	7	2
203	Reliability of DNMSQuest as a Screening Tool for Mood Disorders in Cervical Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 925-931	2.2	1
202	A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene. <i>Neurobiology of Aging</i> , 2021 , 106, 343.e1-343.e8	5.6	2
201	Adult onset dystonia: A disorder of the collicular-pulvinar-amygdala network. <i>Cortex</i> , 2021 , 143, 282-289, 3.8		1
200	Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing. <i>Movement Disorders</i> , 2020 , 35, 877-880	7	1
199	Mood disorder affects age at onset of adult-onset cervical dystonia. <i>Clinical Parkinsonism & Related Disorders</i> , 2020 , 3, 100049	0.9	5
198	A Headset Method for Measuring the Visual Temporal Discrimination Threshold in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 4, 249	2	2
197	Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia. <i>Frontiers in Neurology</i> , 2020 , 11, 991	4.1	4
196	Social cognition in cervical dystonia: A case-control study. <i>Clinical Parkinsonism & Related Disorders</i> , 2020 , 3, 100072	0.9	5
195	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. <i>Neurology</i> , 2020 , 95, 695-697	6.5	
194	Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients. <i>Frontiers in Integrative Neuroscience</i> , 2019 , 13, 8	3.2	2

193	A novel GNAL mutation in familial dystonia presenting with childhood tremor and myoclonus. <i>Movement Disorders</i> , 2019 , 34, 923-924	7	4
192	Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia - two sides of the same coin?. <i>Parkinsonism and Related Disorders</i> , 2019 , 68, 4-7	3.6	1
191	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101863	4	12
190	A Study of the Midbrain Network for Covert Attentional Orienting in Cervical Dystonia Patients using Dynamic Causal Modelling. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> ,	0.9	1
189	Characterizing Brain Network Topology in Cervical Dystonia Patients and Unaffected Relatives via Graph Theory. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2019 , 1694-1697	0.9	
188	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
187	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 591-600	5	9
186	New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 867-870	5	18
185	Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	1
184	Machine Learning EEG to Predict Cognitive Functioning and Processing Speed Over a 2-Year Period in Multiple Sclerosis Patients and Controls. <i>Brain Topography</i> , 2018 , 31, 346-363	4.3	17
183	Cognitive dysfunction in early multiple sclerosis: a review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018 , 111, 359-364	2.7	29
182	Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 552-553	5	3
181	Reduced Frequency of Ipsilateral Express Saccades in Cervical Dystonia: Probing the Nigro-Tectal Pathway. <i>Tremor and Other Hyperkinetic Movements</i> , 2018 , 8, 592	2	2
180	Trials of Licenced RRMS DMTs in Progressive MS 2018 , 207-232		
179	The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. <i>Movement Disorders</i> , 2018 , 33, 232-237	7	11
178	2017 McDonald diagnostic criteria: A review of the evidence. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 48-54	4	28
177	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 253-265	5	105
176	Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 13, 75-80	4	17

175	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , 2017 , 16, 271-281	24.1	101
174	Effects of vitamin D in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317727296	2	9
173	Marta Elian: Obituary. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 370-371	5	
172	A comparison of stimulus presentation methods in temporal discrimination testing. <i>Physiological Measurement</i> , 2017 , 38, N57-N64	2.9	4
171	Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms. <i>Scientific Reports</i> , 2017 , 7, 16753	4.9	14
170	Practice does not make perfect: Temporal discrimination in musicians with and without dystonia. <i>Movement Disorders</i> , 2017 , 32, 1791-1792	7	2
169	Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. <i>European Journal of Neurology</i> , 2017 , 24, 73-81	6	41
168	Menstrual cycle and the temporal discrimination threshold. <i>Physiological Measurement</i> , 2017 , 38, N65-N72		1
167	Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia. <i>Frontiers in Neurology</i> , 2017 , 8, 625	4.1	34
166	All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 876-7	5	2
165	A useful annual review of cognition in relapsing MS is beyond most neurologists - Commentary. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 730-2	5	4
164	Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - Commentary. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1130-1	5	
163	Neural correlates of abnormal sensory discrimination in laryngeal dystonia. <i>NeuroImage: Clinical</i> , 2016 , 10, 18-26	5.3	32
162	Sun exposure is an environmental factor for the development of blepharospasm. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 420-4	5.5	14
161	Modeling the course and outcomes of MS is statistical twaddle--Commentary. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 144-5	5	
160	A 10-year follow-up of the European multicenter trial of interferon β 1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 533-43	5	18
159	Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. <i>PLoS ONE</i> , 2016 , 11, e0146084	3.7	8
158	Exploring the unknown: electrophysiological and behavioural measures of visuospatial learning. <i>European Journal of Neuroscience</i> , 2016 , 43, 1128-36	3.5	1

157	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016 , 23, 772-9	6	5
156	Application of virtual reality head mounted display for investigation of movement: a novel effect of orientation of attention. <i>Journal of Neural Engineering</i> , 2016 , 13, 056006	5	8
155	We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 39-40	5	
154	The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway - Commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 856-7	5	
153	Unmet needs of multiple sclerosis patients in the community. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 144-50	4	18
152	An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 331-5	5.5	15
151	The best basic science paper in multiple sclerosis in 2014: citicoline, remyelination and neuroprotection: commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 374-5	5	1
150	Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders. <i>Journal of Neural Engineering</i> , 2015 , 12, 046026	5	5
149	Symptomatic therapy in multiple sclerosis: Big pharma should do more--commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 982-3	5	2
148	A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 521-5	4	41
147	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1242-3	5	3
146	Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 103-18	5.3	38
145	Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1374-5	5	1
144	Neurodegeneration in multiple sclerosis is a process separate from inflammation: No. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1628-31	5	13
143	Young Women do it Better: Sexual Dimorphism in Temporal Discrimination. <i>Frontiers in Neurology</i> , 2015 , 6, 160	4.1	10
142	Age-Related Sexual Dimorphism in Temporal Discrimination and in Adult-Onset Dystonia Suggests GABAergic Mechanisms. <i>Frontiers in Neurology</i> , 2015 , 6, 258	4.1	14
141	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis--commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 136-7	5	1
140	Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. <i>European Journal of Neurology</i> , 2015 , 22, 570-7	6	11

139	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015 , 84, 1145-52	6.5	47
138	A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0127960	3.7	37
137	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. <i>Current Medical Research and Opinion</i> , 2014 , 30, 613-27	2.5	53
136	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 253-7	5	36
135	MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 284-5	5	1
134	Dexterity training improves manual precision in patients affected by essential tremor. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014 , 95, 705-10	2.8	10
133	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 513-9	4	32
132	Multiparity in women with multiple sclerosis causes less long-term disability: commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1437-8	5	3
131	The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1817-8	5	2
130	Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1169-70	5	1
129	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1690-1	5	6
128	Temporal discrimination, a cervical dystonia endophenotype: penetrance and functional correlates. <i>Movement Disorders</i> , 2014 , 29, 804-11	7	54
127	Economic costs associated with an MS relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 678-83	4	30
126	Epidemiology of Wilson's disease in Ireland. <i>Movement Disorders</i> , 2014 , 29, 1567-8	7	13
125	Electrophysiological and behavioral measures of visuo-motor learning for application in movement disorders. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2014 , 2014, 3533-6	0.9	
124	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1302-3	5	5
123	Cervical dystonia: a disorder of the midbrain network for covert attentional orienting. <i>Frontiers in Neurology</i> , 2014 , 5, 54	4.1	31
122	A headset method for measuring the visual temporal discrimination threshold in cervical dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2014 , 4, 249	2	3

121	Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double-blind placebo-controlled trial. <i>Trials</i> , 2013 , 14, 272	2.8	16
120	Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>N Engl J Med</i> 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.	4	28
119	Evoked potentials are of little use in the diagnosis or monitoring of MS: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1824-5	5	6
118	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , 2013 , 260, 2286-96	5.5	50
117	The endophenotype and the phenotype: temporal discrimination and adult-onset dystonia. <i>Movement Disorders</i> , 2013 , 28, 1766-74	7	52
116	DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, e2.92-e2	5.5	3
115	The best clinical paper on multiple sclerosis in 2012: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 522-3	5	1
114	Response to comment on the article by Allen et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 509	5	1
113	Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1694-5	5	2
112	The best basic science paper on multiple sclerosis in 2012: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1130-1	5	
111	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 861-2	5	3
110	A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1095-100	5	22
109	If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 143-4	5	2
108	One can prevent post-partum MS relapses by exclusive breast feeding: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1569-70	5	8
107	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 719-20	5	7
106	Symptom overlap in anxiety and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1349-54	5	15
105	A novel CACNA1A mutation associated with adult-onset, paroxysmal head tremor. <i>Movement Disorders</i> , 2013 , 28, 842-3	7	8
104	In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 29-30	5	5

103	Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. <i>Movement Disorders</i> , 2013 , 28, 1874-7	7	25
102	Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies 2013 , 187-219		
101	Temporal discrimination thresholds in adult-onset primary torsion dystonia: an analysis by task type and by dystonia phenotype. <i>Journal of Neurology</i> , 2012 , 259, 77-82	5.5	63
100	Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 367, 1087-97	59.2	943
99	Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis. <i>PLoS ONE</i> , 2012 , 7, e45536	3.7	12
98	A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1797-800	5	38
97	Using atypical symptoms and red flags to identify non-demyelinating disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 44-8	5.5	18
96	THE COST OF A MULTIPLE SCLEROSIS RELAPSE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, A18.3-A18	5.5	
95	Spontaneous intracranial hypotension: case reports and literature review. <i>Irish Journal of Medical Science</i> , 2012 , 181, 171-7	1.9	7
94	A budget impact analysis of natalizumab use in Ireland. <i>Irish Journal of Medical Science</i> , 2012 , 181, 199-204		12
93	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012 , 259, 898-905	5.5	54
92	There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 930-1	5	7
91	Does natalizumab therapy worsen neuromyelitis optica?. <i>Neurology</i> , 2012 , 79, 1065-6	6.5	70
90	Truly benign multiple sclerosis is rare: let's stop fooling ourselves--commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 15	5	13
89	The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 561-2	5	
88	Rehabilitation therapy in MS: a short-term, expensive, placebo: commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1382-3	5	2
87	In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan!--Commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 269-70	5	
86	040 Electronic neurology referrals: a solution for an overburdened healthcare system?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, e1.205-e1	5.5	

85	We are about to cure MS in the next 10 years, even though we do not know its cause: commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 786-7	5	1
84	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1213-4	5	
83	Do not treat from CIS onset: evaluate disease course and prognosis first--commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 396-7	5	4
82	Deaths and disability from natalizumab are no longer tolerable: Commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1073	5	2
81	The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1684-5	5	
80	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: commentary. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1533	5	3
79	Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2011 , 305, 45-52	3.2	12
78	Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. <i>Brain</i> , 2011 , 134, 2656-63	11.2	46
77	Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2011 , 18, 792-5	6	14
76	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
75	Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 317-22	5.5	48
74	Controversies in multiple sclerosis: a series of debates. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1170	5	
73	The major cause of multiple sclerosis is environmental: genetics has a minor role--commentary. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1176	5	6
72	POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, e58-e58	5.5	
71	Obituary. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 518-519	5	1
70	Clinically isolated syndrome: a protected zone for trials of new therapies?. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 754-5	5	3
69	Natalizumab therapy of multiple sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 787-9	3.5	2
68	OAS1: a multiple sclerosis susceptibility gene that influences disease severity. <i>Neurology</i> , 2010 , 75, 411-8.5	8.5	24

67	PAW29 Multiple sclerosis in Ireland: regional variation in prevalence and vitamin D status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, e31-e31	5.5	
66	PONM12 Multifocal motor neuropathy due to infliximab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, e63-e63	5.5	2
65	New perspectives in the natural history of multiple sclerosis. <i>Neurology</i> , 2010 , 74, 2004-15	6.5	199
64	Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. <i>Neurology</i> , 2010 , 74 Suppl 3, S24-35	6.5	36
63	A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls. <i>Clinical Neurophysiology</i> , 2010 , 121, 1420-1426	4.3	25
62	Comparing endophenotypes in adult-onset primary torsion dystonia. <i>Movement Disorders</i> , 2010 , 25, 84-90		28
61	Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation. <i>Muscle and Nerve</i> , 2010 , 41, 265-9	3.4	14
60	Temporal discrimination threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia. <i>Brain</i> , 2009 , 132, 2327-35	11.2	117
59	Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. <i>Pharmacogenomics</i> , 2009 , 10, 1177-86	2.6	41
58	Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1528-31	5	20
57	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology</i> , 2009 , 8, 254-60	24.1	348
56	Cervical dystonia presenting as a phenocopy in an Irish SCA2 family. <i>Movement Disorders</i> , 2009 , 24, 466-77		1
55	Phenotypic diversity associated with the mitochondrial m.8313G>A point mutation. <i>Muscle and Nerve</i> , 2009 , 40, 648-51	3.4	1
54	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009 , 256, 405-15	5.5	164
53	Predicting and preventing the future: actively managing multiple sclerosis. <i>Practical Neurology</i> , 2009 , 9, 133-43, discussion 144	2.4	11
52	Assessing disability progression with the Multiple Sclerosis Functional Composite. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 984-97	5	73
51	Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. <i>Brain</i> , 2009 , 132, 1753-63	11.2	106
50	Differential diagnosis of suspected multiple sclerosis: a consensus approach. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1157-74	5	450

49	REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. <i>Brain</i> , 2008 , 131, 1078-86	11.2	138
48	Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. <i>Neurology</i> , 2008 , 71, 1291-2	6.5	262
47	Intravenous therapy for the treatment of multiple sclerosis. <i>Future Prescriber</i> , 2008 , 8, 15-20		1
46	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007 , 62, 335-46	9.4	136
45	Linkage to a known gene but no mutation identified: comprehensive reanalysis of SPG4 HSP pedigrees reveals large deletions as the sole cause. <i>Human Mutation</i> , 2007 , 28, 739-40	4.7	9
44	Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia. <i>Movement Disorders</i> , 2007 , 22, 2443-6	7	31
43	Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. <i>Journal of Neurology</i> , 2007 , 254, 1547-54	5.5	9
42	Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 336-42	5	31
41	Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 980-3	5.5	32
40	The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. <i>Neurology</i> , 2007 , 69, 1391-403	6.5	263
39	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. <i>Neurology</i> , 2007 , 68, 1299-304	10.4	107
38	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. <i>Neurology</i> , 2007 , 68, 1390-401	6.5	260
37	Natalizumab: A new treatment for relapsing remitting multiple sclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 259-68	2.9	68
36	The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 599-604	5	17
35	A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 354, 899-910	59.2	2432
34	Unrecognised symptoms of depression in a community-based population with multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 219-23	5.5	71
33	Paroxysmal torticollis and blepharospasm following bilateral cerebellar infarction. <i>Journal of Neurology</i> , 2006 , 253, 1644-5	5.5	30
32	Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 46-50	5	113

31	Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 635-46	6.1	63
30	Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. <i>Journal of Neurology</i> , 2005 , 252, 1245-8	5.5	13
29	Sensory abnormalities in unaffected relatives in familial adult-onset dystonia. <i>Neurology</i> , 2005 , 65, 938-40	4.5	47
28	Age at onset as a factor in determining the phenotype of primary torsion dystonia. <i>Neurology</i> , 2004 , 63, 1423-6	6.5	72
27	Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 572-6	5.5	57
26	Cervical dystonia following peripheral trauma--a case-control study. <i>Journal of Neurology</i> , 2004 , 251, 150-5	5.5	31
25	Inherited myoclonus-dystonia and epilepsy: further evidence of an association?. <i>Movement Disorders</i> , 2004 , 19, 1456-9	7	24
24	Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. <i>Brain</i> , 2004 , 127, 1353-60	11.2	461
23	Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. <i>Neurology</i> , 2004 , 62, 407-10	6.5	42
22	CADASIL imitating multiple sclerosis: the importance of MRI markers. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 430-2	5	29
21	The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 72, 43-6	5.5	47
20	Leigh disease associated with a novel mitochondrial DNA ND5 mutation. <i>European Journal of Human Genetics</i> , 2002 , 10, 141-4	5.3	79
19	Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. <i>Neurology</i> , 2001 , 57, 1870-5	6.5	59
18	SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. <i>Neurology</i> , 2001 , 56, 1230-3	6.5	62
17	Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p. <i>Neurology</i> , 2000 , 54, 1510-7	6.5	48
16	Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. <i>Human Molecular Genetics</i> , 2000 , 9, 637-44	5.6	196
15	Phenotype of AD-HSP due to mutations in the SPAST gene: comparison with AD-HSP without mutations. <i>Neurology</i> , 2000 , 55, 1794-800	6.5	39
14	Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance. <i>European Journal of Human Genetics</i> , 1998 , 6, 275-82	5.3	25

13	The incidence of sudden unexpected death in epilepsy (SUDEP) in South Dublin and Wicklow. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1998 , 7, 355-8	3.2	51
12	Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. <i>New England Journal of Medicine</i> , 1998 , 339, 285-91	59.2	1137
11	Royal Academy of Medicine in Ireland Section of Pathology. <i>Irish Journal of Medical Science</i> , 1997 , 166, 267-269	1.9	
10	Neuropsychological assessment in multiple sclerosis: methodological issues and concerns. <i>Multiple Sclerosis Journal</i> , 1996 , 2, 57-65	5	10
9	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. <i>American Journal of Human Genetics</i> , 1996 , 58, 171-81	11	34
8	The Functional Limitations Profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. <i>Journal of Neurology</i> , 1995 , 242, 650-7	5.5	11
7	Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). <i>Annals of Neurology</i> , 1995 , 38, 817-24	9.4	73
6	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR findings. <i>American Journal of Neuroradiology</i> , 1995 , 16, 2115-9	4.4	31
5	Pregnancy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993 , 56, 1043-5	5.5	21
4	An epidemiological study of Wilson's disease in the Republic of Ireland. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993 , 56, 298-300	5.5	54
3	Bipolar affective disorder prior to the onset of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1993 , 88, 388-93	3.8	31
2	Wilson's disease and the neuroleptic malignant syndrome. <i>Irish Journal of Psychological Medicine</i> , 1990 , 7, 138-139	3	4
1	Irish neurological association. <i>Irish Journal of Medical Science</i> , 1984 , 153, 152-157	1.9	